Related Experiment Video
Updated: Aug 10, 2026
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Early first-trimester sibutramine exposure : pregnancy outcome and neonatal follow-up
Marco De Santis1, Gianluca Straface, Anna F Cavaliere
1Department of Obstetrics and Gynecology, Telefono Rosso - Teratology Information Service, Catholic University of the Sacred Heart, Rome, Italy. marcodesantis@rm.unicatt.it
Background:
Sibutramine is a drug that is used in the treatment of obesity. There are currently no epidemiological studies relating to sibutramine exposure in pregnancy. The objective of our study was to determine whether sibutramine exposure during pregnancy constitutes a risk factor to the mother and developing fetus.
Methods:
Fifty-two pregnant women who were exposed to sibutramine in the first trimester of pregnancy, when they were unaware of being pregnant, contacted our Teratology Information Service. We recorded the prospective outcomes of this case series between May 2001 and September 2004 with a complete neonatal follow-up up to 1 month after delivery.
Results:
Seven cases of hypertensive complications were observed during pregnancies. No cases of congenital anomalies in neonates were observed.
Conclusion:
Although many more cases are necessary to demonstrate that sibutramine is not teratogenic in pregnancy, our experience improves the counseling of pregnancies occurring involuntarily during sibutramine therapy.
More Related Videos
15:27Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development
Published on: July 13, 2014
05:13Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
Published on: February 28, 2025
